World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0000254717
Reproduction Date:

Title: Gentamicin  
Author: World Heritage Encyclopedia
Language: English
Subject: Aminoglycoside, Pathogenic bacteria, Fusidic acid, Chloramphenicol, Tetracycline
Collection: Aminoglycoside Antibiotics, Otologicals, Rtt, Toxicology, World Health Organization Essential Medicines
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
Clinical data
Trade names Genticyn, Garamycin, Magenta, Merigenta and others
  • D
Legal status
Routes of
IV, eye drop, IM, topical
Pharmacokinetic data
Bioavailability limited oral bioavailability
Protein binding 0-10%
Biological half-life 2 hrs
Excretion renal
CAS Registry Number  Y
ATC code D06 J01 S01 S02 S03 QA07 QG01 QG51 QJ51
PubChem CID:
DrugBank  N
ChemSpider  Y
Chemical data
Formula C21H43N5O7
Molecular mass 477.596 g/mol

Gentamicin, sold under the brandname Garamycin among other, is an health system.[6] It is available as a generic medication.[7] It wholesale cost is between 0.05 and 0.58 USD per day.[8]


  • Medical uses 1
  • Side effects 2
    • Inner ear 2.1
    • Kidneys 2.2
  • Mechanism of action 3
    • Components 3.1
  • History 4
  • Research 5
  • References 6

Medical uses

Active against a wide range of bacterial infections, mostly Gram-negative bacteria including Pseudomonas, Proteus, Serratia, and the Gram-positive Staphylococcus.[9]

Gentamicin is not used for tularemia seen often in hunters and/or trappers).[10]

Some Enterobacteriaceae, Pseudomonas spp., enterococci, Staphylococcus aureus and other staphylococci are resistant to gentamicin sulfate, to varying degrees.[11]

Side effects

Side effects of gentamicin toxicity vary between people. Side effects may become apparent shortly after or up to months after gentamicin is administered. Symptoms of gentamicin toxicity include:

  • Balance difficulty
  • Bouncing, unsteady vision
  • Ringing in the ears (tinnitus)
  • Difficulty multi-tasking, particularly when standing

Gentamicin is nephrotoxic. Risk factors for aminoglycoside nephrotoxicity include patient factors such as:

  • increased age
  • reduced renal function
  • pregnancy
  • hypothyroidism
  • hepatic dysfunction
  • volume depletion
  • metabolic acidosis
  • concurrent use of other drugs: vancomycin, NSAIDs, cisplatin, cyclosporin, cephalosporin, diuretics
  • Concurrent use of iodinated contrast agents

Treatment factors can also affect toxicity. Important factors such as dose, frequency, levels and duration of therapy can affect level of toxicity.

Psychiatric symptoms related to gentamicin can occur. These include anorexia, confusion, depression, disorientation and visual hallucinations.[12]

A number of factors and determinants should be taken into account when using gentamicin, including differentiation between empirical and directed therapy which will affect dosage and treatment period.[3] Many medical practitioners freely administer gentamicin as an antibiotic without advising people of the severe and permanent potential ramifications of its use. Gentamicin is a low-cost medicine when compared with alternatives, and is typically US$3–6 per dosage less than alternatives.

Inner ear

Aminoglycosides are toxic to the sensory cells of the ear, but they vary greatly in their relative effects on hearing versus balance. Gentamicin is a vestibulotoxin, and can cause permanent loss of equilibrioception, caused by damage to the vestibular apparatus of the inner ear, usually if taken at high doses or for prolonged periods of time, but there are well documented cases in which gentamicin completely destroyed the vestibular apparatus after three to five days. A small number of affected individuals have a normally harmless mutation in their mitochondrial DNA encoding the 12S ribosomal RNA (m.1555 A>G), that allows the gentamicin to affect their cells.[13] The cells of the ear are particularly sensitive to this, sometimes causing complete hearing loss.[14] However, gentamicin is sometimes used intentionally for this purpose in severe Ménière's disease, to disable the vestibular apparatus. These side effects are most common when the drug is administered via drops directly to the ear.


Prevention of nephrotoxicity includes judicious use of IV fluids to correct and avoid volume depletion, correction of hypokalemia and hypomagnesemia. Once daily dosing has been shown to be less toxic than multiple daily doses. Gentamicin is usually dosed by ideal body weight. Various formulae exist for calculating gentamicin dosage. Trough and peak serum levels of gentamicin are monitored during treatment to individualize therapy and prevent excess exposure.[15]

Gentamicin, like other aminoglycosides, causes nephrotoxicity by inhibiting protein synthesis in renal cells. This mechanism specifically causes necrosis of cells in the proximal tubule, resulting in acute tubular necrosis which can lead to acute renal failure.[16]

Mechanism of action

Gentamicin is a bactericidal antibiotic that works by irreversibly binding the 30S subunit of the bacterial ribosome, interrupting protein synthesis. This mechanism of action is similar to other aminoglycosides.[17] Gentamicin is a bactericidal antibiotic.


Gentamicin is composed of a number of related gentamicin components and fractions which have varying degrees of antimicrobial potency.[18] The main components of gentamicin include members of the gentamicin C complex: gentamicin C1, gentamicin C1a, and gentamicin C2 which compose approximately 80% of gentamicin and have been found to have the highest antibacterial activity. Gentamicin A, B, X, and a few others make up the remaining 20% of gentamicin and have lower antibiotic activity than the gentamicin C complex.[19] The exact composition of a given sample or lot of gentamicin is not well defined, and the level of gentamicin C components or other components in gentamicin may differ from lot-to-lot depending on the gentamicin manufacturer or manufacturing process. Because of this lot-to-lot variability, it can be difficult to study various properties of gentamicin including pharmacokinetics and microorganism susceptibility if there is an unknown combination of chemically related but different compounds.[20]


Gentamicin for injection

Gentamicin is produced by the fermentation of Micromonospora purpurea. It was discovered in 1963 by Weinstein, Wagman et al. at Schering Corporation in Bloomfield, N.J. working with source material (soil samples) provided by Rico Woyciesjes.[21] Subsequently it was purified and the structures of its three components determined by Cooper, et al., also at the Schering Corporation. It was initially used as a topical treatment for burns at the Atlanta and San Antonio burn units and was introduced into IV usage in 1971. It remains a mainstay for use in sepsis.

It is synthesized by Micromonospora, a genus of Gram-positive bacteria widely present in the environment (water and soil). To highlight their specific biological origins, gentamicin and other related antibiotics produced by this genus (verdamicin, mutamicin, sisomicin, netilmicin, retymicin) generally have their spellings ending in ~micin and not in ~mycin.


Gentamicin is also used in molecular biology research as an antibacterial agent in tissue and cell culture, to prevent contamination of sterile cultures. Gentamicin is one of the few heat-stable antibiotics that remain active even after autoclaving, which makes it particularly useful in the preparation of some microbiological growth media.


  1. ^ a b c d e f g "Gentamicin Sulfate". The American Society of Health-System Pharmacists. Retrieved Aug 15, 2015. 
  2. ^ Bartlett, Jimmy (2013). Clinical Ocular Pharmacology (s ed.). Elsevier. p. 214.  
  3. ^ a b Moulds, Robert and Jeyasingham, Melanie (October 2010). "Gentamicin: a great way to start". Australian Prescriber (33): 134–135. 
  4. ^ "Gentamicin use while Breastfeeding". Retrieved 15 August 2015. 
  5. ^ Pucci, edited by Thomas Dougherty, Michael J.; Weinstein, Marvin J. (2011). Handbook of antibiotic discovery and development (2012 ed.). New York: Springer. p. 238.  
  6. ^ "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014. 
  7. ^ Burchum, Jacqueline (2014). Lehne's Pharmacology for Nursing Care. Elsevier Health Sciences. p. 1051.  
  8. ^ "Gentamicin Sulfate". International Drug Price Indicator Guide. Retrieved 15 August 2015. 
  9. ^ Gentamicin: Drug Information Provided by Lexi-Comp: Merck Manual Professional
  10. ^ Goljan, Edward F. (2011). Rapid Review Pathology (3rd ed.). Philadelphia, PA: Elsevier. p. 241.  
  11. ^ "Gentamicin spectrum of bacterial susceptibility and Resistance" (PDF). Retrieved 15 May 2012. 
  12. ^ Giannini, A.J.; Black, H.R. (1978). Psychiatric, Psychogenic and Somatopsychic Disorders Handbook. Garden City, New York: Medical Examination Publishing Co. pp. 136–137.  
  13. ^ Pandya, A (1993). Pagon, R. A.; Adam, M. P.; Ardinger, H. H.; Bird, T. D.; Dolan, C. R.; Fong, C. T.; Smith, R. J. H.; Stephens, K, eds. "Nonsyndromic Hearing Loss and Deafness, Mitochondrial".  
  14. ^ Gentamicin Toxicity at the American Hearing Research Foundation
  15. ^ Lopez-Novoa, Jose (2011). "New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view.". Kidney International 79: 33–45.  
  16. ^ Sundin, D.P.; Sandoval, R.; Molitoris, B.A. (2001). "Gentamicin Inhibits Renal Protein and Phospholipid Metabolism in Rats: Implications Involving Intracellular Trafficking". J Am Soc Nephrol 12: 114–123. 
  17. ^ 
  18. ^ Weinstein, Marvin J. (1967). "Biological Activity of the Antibiotic Components of the Gentamicin Complex". Journal of Bacteriology 94.3: 789–790. 
  19. ^ Vydrin, A. F. (2003). "Component Composition of Gentamicin Sulfate Preparations". Pharmaceutical Chemistry Journal 37.8: 448–449. 
  20. ^ Isoherranen, Nina; Eran, Lavy (2000). "Pharmacokinetics of Gentamicin C1, C1a, and C2 in Beagles after a Single Intravenous Dose". Antimicrobial Agents and Chemotherapy 44.6: 1443–1447. 
  21. ^ Weinstein, Marvin; Wagman (1963). "Gentamicin, A New Antimicrobial Complex from Micromonospora". J Med Chem 6: 463–464.  
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.